Hypophosphatasia in Adults: Clinical Spectrum and Its Association With Genetics and Metabolic Substrates.

Autor: Lefever, Eveline; Witters, Peter; Gielen, Evelien; Vanclooster, Annick; Meersseman, Wouter; Morava, Eva; Cassiman, David; Laurent, Michaël R.

Publication year: 2020

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry

issn:1094-6950

doi: 10.1016/j.jocd.2018.12.006

Abstract:

BACKGROUND: Hypophosphatasia (HPP) is a rare metabolic bone disorder caused by mutations in the alkaline phosphatase (ALPL) gene, and characterized by low circulating alkaline phosphatase (ALP) levels and bone, muscle, dental and systemic manifestations. In this case series we investigate the clinical spectrum, genetic and biochemical profile of adult HPP patients from the University Hospitals Leuven, Belgium. METHODOLOGY: Adults with HPP were identified through medical record review. Inclusion criteria were: (1) age ≥ 16 yr; (2) consecutively low ALP levels not explained by secondary causes; (3) one or more of the following supporting criteria: biochemical evidence of elevated enzyme substrates; subtrochanteric fractures, metatarsal fractures or other typical clinical features; family history of HPP; a known or likely pathogenic ALPL mutation. RESULTS: Nineteen patients met our inclusion criteria (n = 2 infantile, n = 6 childhood, n = 10 adult-onset HPP and one asymptomatic carrier). Fractures and dental abnormalities were the most reported symptoms. Fatigue was reported in n = 7/19 patients (37%), three of which had previously been misdiagnosed as having chronic fatigue syndrome and/or fibromyalgia. Empirical pyridoxine therapy in four patients (without seizures) did not provide symptomatic relief. N = 7/19 patients (37%) were inappropriately treated or planned to be treated with antiresorptive treatment. Two patients developed atypical femoral fractures following exposure to bisphosphonates and/or denosumab. Patients detected by screening were less severely affected, while patients with homozygous or compound heterozygous mutations had the most severe symptoms, significantly lower circulating ALP levels (p = 0.013) and significantly higher pyridoxal-5′-phosphate (p = 0.0018) and urinary phosphoethanolamine (p = 0.0001) concentrations. CONCLUSIONS: Screening may detect mainly less severely affected individuals, which may nevertheless avoid misdiagnosis and inappropriate antiresorptive drug exposure. Patients with biallelic mutations had more severe symptoms, significantly lower ALP and higher substrate levels. Whether the latter finding has implications for the classification and treatment of HPP should be investigated further in larger cohorts.

Language: eng

Pmid: 30655187

Tags: Humans; Aged; Aged, 80 and over; Female; Male; Adult; Middle Aged; Adolescent; Young Adult; Severity of Illness Index; Adults; Alkaline phosphatase; Alkaline Phosphatase/*genetics/metabolism; Bone Density Conservation Agents/adverse effects; Denosumab/adverse effects; Diphosphonates/adverse effects; Epilepsy/drug therapy/etiology/physiopathology; Ethanolamines/*urine; Fatigue/etiology/physiopathology; Femoral Fractures/chemically induced/etiology/physiopathology; fractures; Fractures, Bone/*physiopathology; Fractures, Ununited/etiology/physiopathology; Growth Disorders/etiology/physiopathology; Hip Fractures/etiology/physiopathology; hypophosphatasia; Hypophosphatasia/complications/genetics/*metabolism/physiopathology; Kidney Calculi/etiology/physiopathology; Metatarsal Bones/injuries; phosphoethanolamine; Pyridoxal Phosphate/*blood; pyridoxal-5’-phosphate; Pyridoxine/therapeutic use; Rickets, Hypophosphatemic/etiology/physiopathology; Tooth Loss/etiology/physiopathology; Vitamin B Complex/therapeutic use

Link: https://pubmed.ncbi.nlm.nih.gov/30655187/